PATIENT ALERT: Information regarding COVID-19. 

Clinical Research & Trials

USO 20431

A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)(G1T28-208)


Disease Types: Breast Cancer Research

Eligibility Requirements:

-Locally advanced unresectable or metastatic triple negative breast cancer
-No: previous treatment with gemcitabine; acute CNS or leptomeningeal disease requiring treatment; prior stem cell or bone marrow transplant; uncontrolled ischemic heart disease or congestive heart failure, historyof stroke or CVA within last 6 months; known serious active infection such as HIV, Hep B, Hep C, or TB

Available at: